HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-wrinkle serums disappoint Consumer Reports

This article was originally published in The Rose Sheet

Executive Summary

Consumers looking to fight the signs of aging should spend money on sunscreens and moisturizers rather than nine over-the-counter anti-wrinkle face serums tested by Consumer Reports, the non-profit organization asserts in an April 6 release. Featured in the May issue of Consumer Reports magazine, the test on 79 participants between the ages of 40 and 65 found that results of the serums were inconsistent, some serums producing a visual change in wrinkle length or depth for some test subjects while doing nothing for others, though all the serums claim to reduce the appearance of fine lines and wrinkles within six weeks or less. "When there were any wrinkle reductions, they were at best slight and fell short of the miracles implied on the product labels," says the organization. Of the products tested, two serums were rated as slightly more effective than others: DermaSilk 5 Minute Face Lift and Neutrogena Ageless Intensives Deep Wrinkle. Burt's Bees Naturally Ageless Intensive Repairing was found to be the least effective at reducing wrinkles, Consumer Reports says. The report is one of three on the anti-aging market and products that promise to turn back the clock

You may also be interested in...



Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

Global Industry Hails Bioequivalence Progress

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

Generics Leaders Trade Places At The Top

In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.

UsernamePublicRestriction

Register

RS016844

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel